Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED BALANCE SHEETS

v3.19.2
CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2018
Dec. 31, 2017
Current assets    
Cash $ 89 $ 142
Prepaid expenses 12,991 3,006
Total current assets 13,080 3,148
Total Assets 13,080 3,148
Current liabilities    
Accounts payable 191,714 270,851
Accrued expenses 421,000 493,164
Accrued interest payable 537,118 382,302
Related party payables 1,423,984 1,026,819
Stock subscriptions payable 1,271
Notes payable - current - related parties * Includes unamortized debt issuance costs related to detached warrants of $8,074 and $19,969 at December 31, 2018 and December 31, 2017, respectively 697,770 630,575
Notes payable - current - non related parties * Includes unamortized beneficial conversion features related to convertible notes of $5,920 and none at December 31,2018 and December 31, 2017, respectively 163,654 163,574
Total current liabilties 3,436,511 2,967,285
Total Liabilities 3,436,511 2,967,285
Stockholders' Deficit    
Preferred stock, $0.00001 par value; 22,000,000 shares authorized, No shares issued or outstanding as of December 31, 2018 and December 31, 2017
Common stock, $0.00001 par value; 800,000,000 shares authorized; 116,751,078 and 109,409,930 shares issued and outstanding as of December 31, 2018 and December 31, 2017, respectively 1,172 1,096
Additional paid-in capital 14,887,804 14,785,051
Accumulated deficit (18,262,136) (17,703,171)
Total TransBiotec, Inc. stockholders' deficit (3,373,146) (2,917,010)
Noncontrolling interest (50,285) (47,127)
Total Stockholders' Deficit (3,423,431) (2,964,137)
Total Liabilities and Stockholders' Deficit 13,080 3,148
Series A Preferred Stock [Member]    
Stockholders' Deficit    
Preferred stock, $0.00001 par value; 22,000,000 shares authorized, No shares issued or outstanding as of December 31, 2018 and December 31, 2017 $ 14 $ 14